Rennova Health, Inc.: management transactions · United States · SEC (Form 4)

About Rennova Health, Inc.

Rennova Health, Inc. is a U.S.-listed healthcare company trading on the OTC market (OTCID: RNVA), historically followed by investors who track highly speculative micro-cap names in the American healthcare space; the company has also been associated at various points with Nasdaq-related filings and capital-market activity. Its corporate headquarters is in West Palm Beach, Florida, United States. From a business-model perspective, Rennova has evolved around integrated solutions for healthcare providers, combining diagnostics, supportive software, and, at different stages of its recent history, hospital-related assets. Recent SEC disclosures describe Rennova as a provider of diagnostics and supportive software solutions to healthcare providers, with an emphasis on helping improve the patient experience and clinical efficiency. The company was launched in 2015 following a merger involving Medytox Solutions and CollabRx, and its subsequent history has been marked by repeated strategic adjustments in response to a challenging reimbursement and financing environment. Rennova’s core business historically centered on clinical laboratory operations, particularly urine and toxicology testing for physicians, clinics, and rehabilitation facilities. Earlier company materials also referenced supportive software offerings such as electronic health records, laboratory information systems, and medical billing services. More recent official communications frame the company more broadly as a vertically integrated healthcare platform that aims to pair diagnostics with software tools in order to deliver a more cohesive offering to providers. That combination has been the company’s main strategic thread, even as the asset mix has shifted over time. Competitively, Rennova operates as a small-cap specialty player in a fragmented market dominated by much larger and better-capitalized diagnostic chains, hospital operators, and healthcare software vendors. It does not compete with the scale, balance-sheet strength, or brand recognition of major U.S. healthcare incumbents. Instead, its value proposition has been centered on niche clinical capabilities, operational flexibility, and the potential to monetize specialized healthcare workflows. This also means the company remains highly exposed to reimbursement dynamics, regulatory pressure, execution risk, and funding constraints. A key recent development was the June 2024 announcement of stock exchange agreements with FOXO Technologies involving two operating subsidiaries, as part of a broader restructuring of Rennova’s healthcare assets. SEC filings in 2025 confirm that the company remains headquartered in West Palm Beach and continue to reflect a healthcare-focused profile anchored in diagnostics and related services. For investors in French-speaking markets, Rennova Health should therefore be viewed as a special-situation name: a long-history U.S. healthcare company with a complex corporate evolution, very small market capitalization, and a risk profile that is materially higher than that of established large-cap healthcare peers.